2 recruiting, 1 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow CD30-Positive Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of CD30-Positive Diffuse Large B-Cell Lymphoma trials Research Report on CD30-Positive Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF - Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Medical College of Wisconsin | 42 | 2026-03-04 | 2026-04-03 |
| Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas C7R.CD30.CAR-EBVST cells - CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type | Phase 1 | Recruiting | Baylor College of Medicine | 90 | 2025-10-27 | 2026-10-02 |
| Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients brentuximab vedotin - CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 32 | 2013-11-01 | 2021-01-05 |
Hodgkin Disease (2) · Lymphoma, Large-Cell, Anaplastic (2) · Leukemia (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1) · Neoplasms (1) · Recurrence (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma, T-Cell (2) · Lymphoproliferative Disorders (2) · Neoplasms by Histologic Type (2) · Disease Attributes (1) · Hematologic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Brentuximab Vedotin (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · sargramostim (1)
Abramson Cancer Center at Penn Medicine (1) · Baylor College of Medicine (1) · Medical College of Wisconsin (1)
United States (3)
Guru Subramanian Guru Murthy, MD, MS (1) · Helen Heslop, MD (1) · Jakub Svoboda, MD (1) · Premal Lulla, MD (1)